A Ring Or Polycyclo Ring System In A Substituent E Is Attached Indirectly To The Carboxamide Nitrogen Or To An Amino Nitrogen In Substituent E By Acyclic Nonionic Bonding Patents (Class 514/630)
-
Publication number: 20120003316Abstract: This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.Type: ApplicationFiled: June 3, 2009Publication date: January 5, 2012Inventors: Deshika Reddy, Oluwatoyin Ayotomilola Adeleke, Viness Pillay, Yahya Choonara
-
Publication number: 20120003158Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.Type: ApplicationFiled: April 8, 2011Publication date: January 5, 2012Inventors: Danny ALEXANDER, Jeffrey SHUSTER, Joshua KORZENIK, Garrett ZELLA
-
Publication number: 20110318351Abstract: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.Type: ApplicationFiled: September 12, 2011Publication date: December 29, 2011Inventor: Ivan Bergstein
-
Publication number: 20110319492Abstract: The present invention features a process for making tablets containing one or more pharmaceutically active agent(s) and one or more binder(s), the method including the steps of (i) applying energy to a powder blend comprising the pharmaceutically active agent(s) and the binder(s) for a sufficient period of time to activate the binder(s) within the powder blend and (ii) forming a predetermined amount of the energy-applied powder blend into the tablets.Type: ApplicationFiled: March 21, 2011Publication date: December 29, 2011Inventors: Joseph R. Luber, Christopher E. Szymczak, Frank J. Bunick, Harry S. Sowden, Leo B. Kriksunov
-
Publication number: 20110301243Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.Type: ApplicationFiled: July 29, 2009Publication date: December 8, 2011Inventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
-
Patent number: 8071651Abstract: Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.Type: GrantFiled: September 14, 2006Date of Patent: December 6, 2011Assignee: Novartis AGInventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Christiane Marti, Dirk Behnke, Stjepan Jelakovic
-
Publication number: 20110293558Abstract: The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable objects, such as cells. In further aspects, the invention relates to methods, devices and compositions for diagnosing and/or characterizing disease based on material properties of biological cells.Type: ApplicationFiled: March 21, 2011Publication date: December 1, 2011Applicant: Massachusetts Institute of TechnologyInventors: Subra Suresh, Jianzhu Chen, Irene Yin-Ting Chang
-
Publication number: 20110294830Abstract: The present invention provides a nitrogen-containing compound represented by formula (I1) (in formula (I1), R0 represents a nitro group or the like, Z represents an optionally substituted aryl group or the like, R3 represents a hydrogen atom or the like, Y represents a nitro group or the like, n represents an integer of 0 to 3, D represents an optionally substituted 5-membered to 8-membered hydrocarbon ring group or heterocyclic group having or not having a substituent other than substituent X, X represents a group represented by formula (II-1) (in formula (II-1), R1 and R2 respectively and independently represent a hydrogen atom or the like), A represents a carbon atom or the like, n1 represents an integer of 0 to 2) or a salt thereof, and an insecticide, miticide, sanitary insect pest control agent, or harmful organism control agent including as an active ingredient thereof the nitrogen-containing compound or the salt thereof.Type: ApplicationFiled: February 5, 2010Publication date: December 1, 2011Applicant: Nippon Soda Co., Ltd.Inventors: Jyun Iwata, Masahiro Kawaguchi, Akiko Mizui
-
Patent number: 8067639Abstract: Crystalline form VI of the compound of formula (I): characterised by its X-ray powder diffraction diagram. Medicinal products containing the same which are useful in treating melatoninergic disorders.Type: GrantFiled: November 6, 2008Date of Patent: November 29, 2011Assignee: Les Laboratoires ServierInventors: Gerard Coquerel, Julie Linol, Lionel Le Pape, Jean-Pierre Lecouve
-
Publication number: 20110287114Abstract: A method of making a gelled composition that includes combining water and an effervescent tablet in a vessel, the effervescent tablet including at least 200 mg gelatin and an effervescent couple that includes an acid and a base, heating an aqueous composition (e.g., in a microwave oven), optionally adding cold water to the heated composition, and chilling the composition for a period sufficient for the composition to form a gel.Type: ApplicationFiled: May 23, 2011Publication date: November 24, 2011Applicant: AMERILAB TECHNOLOGIES, INC.Inventor: Kyle M. Johnson
-
Publication number: 20110288146Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.Type: ApplicationFiled: November 16, 2009Publication date: November 24, 2011Inventors: Nandu Deorkar, James Farina, Liliana Miinea, Sameer Ranadive
-
Publication number: 20110280824Abstract: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.Type: ApplicationFiled: July 26, 2011Publication date: November 17, 2011Applicant: Tyco Healthcare Group LPInventor: Joshua B. Stopek
-
Publication number: 20110268808Abstract: Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; optionally at least one water insoluble, and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at least one pH independent water-insoluble polymer(s) along with one or more pharmaceutically acceptable excipiType: ApplicationFiled: January 8, 2010Publication date: November 3, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sukhjeet Singh, Sanju Dhawan
-
Publication number: 20110262543Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Daniela Cocconi, Rossella Musa
-
Publication number: 20110262547Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.Type: ApplicationFiled: April 1, 2011Publication date: October 27, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Rossella Musa, Daniela Cocconi, Alain Chamayou, Laurence Galet
-
Publication number: 20110263492Abstract: A method for preparing a formulation containing nanoparticles of a compound is described. The method includes forming the compound into nanoparticles and then delivering the nanoparticles directly to a collection media. The collection media is a desired component of the formulation.Type: ApplicationFiled: October 19, 2010Publication date: October 27, 2011Inventors: Nahed M. Mohsen, Thomas A. Armer
-
Publication number: 20110250244Abstract: The present invention relates to a process for producing a solid, coated pharmaceutical composition by a melt coating process. The process is adapted to provide a solid, coated pharmaceutical composition by melt coating, which has a fast release.Type: ApplicationFiled: December 17, 2009Publication date: October 13, 2011Applicant: Losan Pharma GmbHInventors: Peter Kraahs, Stefanie Bold, Lars Fahsel
-
Publication number: 20110230561Abstract: A medical adhesive composition comprising, based upon the total weight of the composition, from about 50 wt. % to about 99.9 wt. % of one or more ?-cyanoacrylate monomers and from about 0.1 wt. % to about 5 wt. % of one or more non-steroidal anti-inflammatory drugs (NSAIDs). Suitable NSAIDs include ibuprofen and acetaminophen. The resulting compositions provide enhances fibroblast proliferation and reduced cytotoxicity compared to compositions that do not contain NSAID.Type: ApplicationFiled: November 17, 2009Publication date: September 22, 2011Inventors: Hongbo Liu, Sandra Gonzalez, Breda Mary Cullen, Derek Walter Silcock
-
Publication number: 20110229530Abstract: The present invention refers to an oral dosage form intended for the time-controlled release of drugs comprising a container for one or more active ingredients optionally in admixture with pharmaceutically acceptable excipients, said container consisting of at least two parts or elements that can be joined together so as to seal the contents, at least one of said elements being composed of one or more hydrophilic polymers that undergo a decrease in the glassy-rubbery transition temperature when in contact with aqueous fluids, except for polymers with pH dependent solubility soluble only at pH values above 5, optionally in admixture with pharmaceutically acceptable excipients, the wall of the elements of the container being of such thickness as to delay the release of the contained drug with respect to the time of administration.Type: ApplicationFiled: July 23, 2009Publication date: September 22, 2011Inventors: Andrea Gazzaniga, Matteo Cerea, Alberto Cozzi, Anastasia Anna Foppoli, Maria Edvige Sangalli, Gianaldo Tavella, Lucia Zema
-
Publication number: 20110229565Abstract: This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be encapsulated in the gelator. Enzymatic or hydrolytic cleavage can be used to release the drugs.Type: ApplicationFiled: September 17, 2009Publication date: September 22, 2011Inventors: Jeffrey M. Karp, Praveen Kumar Vemula, George John, Greg Cruikshank
-
Publication number: 20110223214Abstract: Carboxymethylcellulose, notably sodium carboxymethylcellulose or other alkali metal or alkaline earth metal salts of carboxymethylcellulose, are employed to control solidification time of compositions comprising one or more bioresorbable ceramics, notably a hydratable calcium sulphate, in order to facilitate preparation of a ready-to-use composition for inserting into the body by injection.Type: ApplicationFiled: November 27, 2009Publication date: September 15, 2011Applicant: LIDDS ABInventors: Lars Åke Malmsten, Niklas Axén, Hans Lennernäs, Anders Carlsson
-
Publication number: 20110218214Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.Type: ApplicationFiled: September 9, 2010Publication date: September 8, 2011Applicant: ABBOTT LABORATORIESInventors: James T. Link, Qi Shuai, Martin Winn, Hong Yong
-
Publication number: 20110218158Abstract: Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.Type: ApplicationFiled: September 22, 2009Publication date: September 8, 2011Inventors: Reuben S. Harris, Ming Li
-
Publication number: 20110182997Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.Type: ApplicationFiled: February 2, 2009Publication date: July 28, 2011Applicants: VECTURA LIMITED, INNOVATA BIOMED LIMITEDInventors: David Andrew Lewis, Christina Alexandra Keeble, Nicola Kim Whitfield, Tanya Church
-
Patent number: 7985766Abstract: The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a ? mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.Type: GrantFiled: July 30, 2007Date of Patent: July 26, 2011Assignee: MEDA Pharma GmbH & Co. KGInventors: Joachim Goede, Joachim Maus, Peter Jurgen Cnota, Istvan Szelenyi
-
Patent number: 7981923Abstract: Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.Type: GrantFiled: January 26, 2010Date of Patent: July 19, 2011Assignee: Roche Palo Alto LLCInventors: Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
-
Publication number: 20110150766Abstract: A transdermal patch having a top region containing an antagonist followed by a bottom region containing an agonist, whereby the bottommost end of the bottom region is secured to the skin of the patient for delivering a prescribed dosage of agonist to the patient over a predetermined period of time, the antagonist will be released by migrating or moving from the top region through the bottom region to the patient to prevent overdose. Visual indicators are provided in the patch for changing color to separately indicate the operation of the patch, delivery of prescribed dosage, and/or overdosage.Type: ApplicationFiled: February 23, 2011Publication date: June 23, 2011Inventor: Robert B. Royds
-
Patent number: 7964753Abstract: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Type: GrantFiled: June 7, 2010Date of Patent: June 21, 2011Assignee: Sunovion Pharmaceuticals Inc.Inventors: Gerald J. Tanoury, Chris H. Senanayake, Donald W. Kessler
-
Publication number: 20110130373Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and (b) at least one subcutaneously acceptable inactive ingredient.Type: ApplicationFiled: May 26, 2010Publication date: June 2, 2011Applicant: LITHERA, INC.Inventors: John Daniel Dobak, Kenneth Walter Locke
-
Patent number: 7947852Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.Type: GrantFiled: July 1, 2008Date of Patent: May 24, 2011Assignee: Les Laboratoires ServierInventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Patent number: 7939566Abstract: Crystalline form III of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.Type: GrantFiled: November 10, 2009Date of Patent: May 10, 2011Assignee: Les Laboratoires ServierInventors: Gerard Coquerel, Julie Linol, Jean-Claude Souvie
-
Publication number: 20110105446Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: ApplicationFiled: April 19, 2010Publication date: May 5, 2011Applicant: LITHERA, INC.Inventor: John Daniel Dobak
-
Patent number: 7935731Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Type: GrantFiled: May 25, 2010Date of Patent: May 3, 2011Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Publication number: 20110098359Abstract: A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol which is administered as one to two drops in each eye 4 to 6 hourly. The ophthalmic solution further includes one or more of the following excipients: hydroxypropylmethylcellulose, benzalconium chloride, polyacrylic acid such as Teargel®.Type: ApplicationFiled: July 30, 2008Publication date: April 28, 2011Applicant: Stellenbosch UniversityInventor: David Meyer
-
Publication number: 20110064805Abstract: A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm3/g, containing I-type crystals and having an average particle size of over 30 to 250 ?m, a specific surface area of 0.1 to less than 20 m2/g, a repose angle of 25° to less than 44° and a swelling degree of 5% or more, and characterized by having the property of disintegrating in water.Type: ApplicationFiled: November 9, 2010Publication date: March 17, 2011Applicant: ASAHI KASEI CHEMICALS CORPORATIONInventors: Kazuhiro Obae, Hideki Amakawa, Ichiro Ibuki
-
Publication number: 20110052685Abstract: Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: ApplicationFiled: August 31, 2010Publication date: March 3, 2011Applicant: DEPOMED, INC.Inventors: Sui Yuen Eddie Hou, Thadd Vargas
-
Patent number: 7897646Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.Type: GrantFiled: November 13, 2001Date of Patent: March 1, 2011Assignee: AstraZeneca ABInventors: Carl-Axel Bauer, Jan Trofast
-
Publication number: 20110039940Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: ApplicationFiled: October 21, 2010Publication date: February 17, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. Davis
-
Publication number: 20110027326Abstract: An external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols.Type: ApplicationFiled: March 26, 2009Publication date: February 3, 2011Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventor: Yoshiyuki Hirayama
-
Publication number: 20110028456Abstract: A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.Type: ApplicationFiled: January 12, 2009Publication date: February 3, 2011Applicant: CIPLA LIMITEDInventors: Amar Lulla, Geena Malhotra
-
Publication number: 20110015134Abstract: This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer. It elevates the level of an antiangiogenic drug produced by chromosome 21 preferably Endostatin in plasma preferably at least one day prior to surgery and kept at that high level preferably indefinitely. In one embodiment, the therapy specifically excludes drugs that significantly inhibit the VEGF pathway since that is important for wound healing. This method will prevent results of surgery from stimulating tumor growth and angiogenesis of micrometastatic disease that is much easier to prevent than control after the fact. This can be done indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies.Type: ApplicationFiled: September 22, 2010Publication date: January 20, 2011Inventor: Michael W. Retsky
-
Publication number: 20100324000Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the ?2 adrenergic receptor.Type: ApplicationFiled: November 10, 2008Publication date: December 23, 2010Inventors: Victor Giulio Matassa, Carlos Puig Duran, Maria Prat Quiñones, Laia Sole Fue, Oriol Llera Soldevila
-
Publication number: 20100298328Abstract: 1-Heterocyclylamino-2-hydroxy-3-amino-?-arylalkanes of formula (I) and the salts thereof have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.Type: ApplicationFiled: March 30, 2007Publication date: November 25, 2010Inventors: John J. Baldwin, David A. Claremon, Lawrence W. Dillard, Alexey V. Ishchenko, Jing Yuan, Zhenrong Xu, Gerard McGeehan, Wenguang Zeng
-
Patent number: 7829554Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: GrantFiled: July 13, 2006Date of Patent: November 9, 2010Assignee: Lithera, Inc.Inventor: John D. Dobak
-
Publication number: 20100267772Abstract: The present invention relates to the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.Type: ApplicationFiled: April 21, 2010Publication date: October 21, 2010Inventor: Sandra Willigers
-
Publication number: 20100267836Abstract: Novel melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is O, S or NR8; Y is selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, and R is selected from the group consisting of hydrogen, hydroxyl, —OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and —Z—(CH2)p-A; R1 is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1-C4 alkyl, hydroxy-substituted C3-C8 cycloalkyl, and NHR5, wherein R5 is C1-C3 alkyl or C3-C6 cycloalkyl; R2 is selected from the group consisting of: hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R and R3 may be connected together to form an —O—(CH2)v bridge representing with the carbon atoms to which theType: ApplicationFiled: January 12, 2007Publication date: October 21, 2010Applicants: UNIVERSITA DEGLI STUDI DI MILANO, UNIVERSITA DEGLI STUDI DI URBINO, MCGILL UNIVERSITY, UNIVERSITA DEGLI STUDI DI PARMAInventors: Gabriella Gobbi, Marco Mor, Silvia Rivara, Franco Fraschini, Giorgio Tarzia, Annalida Bedini, Gilberto Spadoni, Valeria Lucini
-
Publication number: 20100260840Abstract: The invention relates to a solid orodispersible pharmaceutical composition of agomelatine, characterised in that it comprises agomelatine and granules consisting of co-dried lactose and starch.Type: ApplicationFiled: June 22, 2010Publication date: October 14, 2010Applicant: LES LABORATOIRES SERVIERInventors: Patrick Wuthrich, Hervé Rolland, Marc Julien, François Tharrault
-
Publication number: 20100249045Abstract: The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.Type: ApplicationFiled: April 26, 2008Publication date: September 30, 2010Applicant: THERAQUEST BIOSCIENCES, INC.Inventor: Najib Babul
-
Publication number: 20100240747Abstract: Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.Type: ApplicationFiled: June 1, 2010Publication date: September 23, 2010Inventor: Otto Phanstiel
-
Publication number: 20100234295Abstract: Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated protein kinase activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.Type: ApplicationFiled: March 15, 2010Publication date: September 16, 2010Inventor: Chien-Hung Chen